| Lipoproteins and Cardiovascular Health | Lifetime | 42 | AU 2 | 99.76 |
| Cancer, Lipids, and Metabolism | Lifetime | 65 | AU 3 | 99.65 |
| Cardiac Imaging and Diagnostics | Lifetime | 122 | AU 2 | 99.77 |
| Coronary Interventions and Diagnostics | Lifetime | 66 | AU 2 | 99.76 |
| Diabetes, Cardiovascular Risks, and Lipoproteins | Lifetime | 62 | AU 6 | 99.67 |
| Atherosclerosis and Cardiovascular Diseases | Lifetime | 53 | AU 1 | 99.41 |
| Pharmaceutical Economics and Policy | Lifetime | 32 | AU 2 | 99.08 |
| Health Systems, Economic Evaluations, Quality of Life | Lifetime | 313 | AU 14 | 99.09 |
| Antiplatelet Therapy and Cardiovascular Diseases | Lifetime | 138 | AU 3 | 99.26 |
| Cerebrovascular and Carotid Artery Diseases | Lifetime | 359 | AU 16 | 98.96 |
| Cardiovascular Disease and Adiposity | Lifetime | 271 | AU 8 | 98.53 |
| Diabetes Treatment and Management | Lifetime | 433 | AU 23 | 98.39 |
| Acute Myocardial Infarction Research | Lifetime | 453 | AU 8 | 98.60 |
| Lipid metabolism and disorders | Lifetime | 217 | AU 10 | 97.54 |
| Cardiovascular Health and Disease Prevention | Lifetime | 656 | AU 29 | 97.21 |
| Aortic Thrombus and Embolism | Lifetime | 46 | AU 3 | 95.41 |
| Neutrophil, Myeloperoxidase and Oxidative Mechanisms | Lifetime | 467 | AU 13 | 96.14 |
| Protein Degradation and Inhibitors | Lifetime | 601 | AU 11 | 95.90 |
| Cholesterol and Lipid Metabolism | Lifetime | 936 | AU 33 | 92.96 |
| Paraoxonase enzyme and polymorphisms | Lifetime | 616 | AU 12 | 73.02 |
| Lipoproteins and Cardiovascular Health | 2021-2025 | 5 | AU 1 | 99.90 |
| Health Systems, Economic Evaluations, Quality of Life | 2021-2025 | 23 | AU 2 | 99.48 |
| Diabetes, Cardiovascular Risks, and Lipoproteins | 2021-2025 | 9 | AU 1 | 99.80 |
| Antiplatelet Therapy and Cardiovascular Diseases | 2021-2025 | 8 | AU 1 | 99.69 |
| Atherosclerosis and Cardiovascular Diseases | 2021-2025 | 6 | AU 1 | 99.33 |
| Cancer, Lipids, and Metabolism | 2021-2025 | 14 | AU 1 | 99.60 |
| Pharmaceutical Economics and Policy | 2021-2025 | 8 | AU 1 | 98.73 |
| Cardiac Imaging and Diagnostics | 2021-2025 | 73 | AU 2 | 99.25 |
| Coronary Interventions and Diagnostics | 2021-2025 | 42 | AU 1 | 99.26 |
| Acute Myocardial Infarction Research | 2021-2025 | 81 | AU 3 | 98.53 |
| Cardiovascular Disease and Adiposity | 2021-2025 | 87 | AU 3 | 95.56 |
| Health and Medical Research Impacts | 2021-2025 | 28 | AU 2 | 94.55 |
| Cardiac Health and Mental Health | 2021-2025 | 181 | AU 8 | 94.12 |
| Diabetes Treatment and Management | 2021-2025 | 470 | AU 17 | 95.09 |
| Lipid metabolism and disorders | 2021-2025 | 115 | AU 4 | 88.25 |
| Blood Pressure and Hypertension Studies | 2021-2025 | 836 | AU 37 | 89.29 |
| Adipokines, Inflammation, and Metabolic Diseases | 2021-2025 | 461 | AU 4 | 84.35 |
| Peptidase Inhibition and Analysis | 2021-2025 | 968 | AU 13 | 86.10 |
| Chemotherapy-induced cardiotoxicity and mitigation | 2021-2025 | 462 | AU 14 | 79.12 |
| Inflammatory mediators and NSAID effects | 2021-2025 | 301 | AU 18 | 76.81 |
| Pericarditis and Cardiac Tamponade | 2021-2025 | 252 | AU 4 | 71.33 |
| Cardiovascular, Neuropeptides, and Oxidative Stress Research | 2021-2025 | 182 | AU 10 | 68.85 |
| Fatty Acid Research and Health | 2021-2025 | 821 | AU 16 | 69.70 |
| Eicosanoids and Hypertension Pharmacology | 2021-2025 | 553 | AU 7 | 65.59 |
| Nuclear Receptors and Signaling | 2021-2025 | 755 | AU 11 | 52.01 |
| Aortic Thrombus and Embolism | 2021-2025 | 137 | AU 3 | 52.05 |
